Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma

• Main Authors: Fatima Bilal (Author), Anne Montfort (Author), Julia Gilhodes (Author), Virginie Garcia (Author), Joëlle Riond (Author), Stéphane Carpentier (Author), Thomas Filleron (Author), Céline Colacios (Author), Thierry Levade (Author), Ahmad Daher (Author), Nicolas Meyer (Author), Nathalie Andrieu-Abadie (Author), Bruno Ségui (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Sphingolipid (SL) metabolism alterations have been frequently reported in cancer including in melanoma, a bad-prognosis skin cancer. In normal cells, de novo synthesized ceramide is mainly converted to sphingomyelin (SM), the most abundant SL, by sphingomyelin synthase 1 (SMS1) and, albeit to a less...